NP
NPCE.US Neuropace Inc
- Market cap
- USD 260M
- P/E
- -
- P/B
- 22.75x
- ROE
- -187.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NPCE.US undervalued?
Graham numberThe Graham number of Neuropace Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neuropace Inc fundamental analysis
No fundamental analysis for Neuropace Inc yet.
Neuropace Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tabl…
Full company profileNeuropace Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neuropace Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 37.0M | 41.1M | 45.2M | 45.5M | 65.4M | 79.9M | 100.0M | 90.7M |
| Gross Profit | 26.5M | 30.3M | 33.4M | 32.5M | 48.1M | 59.1M | 77.2M | 75.2M |
| Operating Income | -22.0M | -13.1M | -23.7M | -40.8M | -27.2M | -21.7M | -16.3M | -17.1M |
| EBITDA | -20.1M | -12.5M | -28.4M | -36.6M | -22.8M | -16.6M | -12.1M | -13.9M |
| Net Income | -30.0M | -24.3M | -36.1M | -47.1M | -33.0M | -27.1M | -21.5M | -21.6M |
| EPS | -2.70 | -2.19 | -2.17 | -1.91 | -1.27 | -0.93 | -0.66 | -0.63 |
| Balance Sheet | ||||||||
| Total Assets | 21.1M | 56.0M | 134M | 114M | 108M | 94.6M | 106M | 94.8M |
| Total Liabilities | 150M | 204M | 60.1M | 79.3M | 87.0M | 86.6M | 86.5M | 83.3M |
| Shareholders' Equity | -129M | -148M | 73.5M | 34.8M | 20.7M | 8.01M | 19.0M | 11.5M |
| Cash & Short-term Investments | 5.09M | 38.1M | 116M | 77.4M | 66.5M | 52.8M | 61.1M | 49.2M |
| Total Debt | 62.8M | 52.9M | 49.8M | 69.8M | 72.4M | 73.3M | 70.8M | 69.5M |
| Cash Flow | ||||||||
| Operating Cash Flow | -25.0M | -21.6M | -24.6M | -36.9M | -19.7M | -17.9M | -11.0M | -16.8M |
| Capital Expenditure | 468K | 62.0K | 384K | 603K | 173K | 306K | 332K | 344K |
| Free Cash Flow | -25.5M | -21.7M | -25.0M | -37.5M | -19.9M | -18.3M | -11.3M | -17.1M |
| Ratios | ||||||||
| ROE | - | - | -49.1% | -135.4% | -159.6% | -338.7% | -112.8% | -187.8% |
| ROA | -142.1% | -43.4% | -27.0% | -41.3% | -30.6% | -28.7% | -20.3% | -22.8% |
| Net Profit Margin | -81.1% | -59.0% | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% | -23.8% |
| Debt to Equity | - | - | 0.68x | 2.01x | 3.51x | 9.15x | 3.72x | 6.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neuropace Inc dividends
Neuropace Inc has not paid dividends in the last 7 fiscal years.
Who owns Neuropace Inc
- Insiders 4.51%
- Institutions 94.06%
- Public & others 1.43%
- Shares outstanding 34.5M
- Free float 25.7M
Top funds holding NPCE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Polar Capital Healthcare Opports Inc | 2.89M | 8.39% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 908K | 2.64% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 673K | 1.96% | 0.00% | Oct 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 438K | 1.27% | 0.00% | Sep 2026 |
| Polar Capital Glb Healthcare Ord | 410K | 1.19% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 288K | 0.84% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 242K | 0.70% | -0.38% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 227K | 0.66% | 0.00% | Sep 2026 |
| Driehaus Micro Cap Growth USD | 178K | 0.52% | +1.42% | Sep 2026 |
| Vanguard Russell 2000 ETF | 154K | 0.45% | +1.16% | Sep 2026 |
| Fidelity Extended Market Index | 121K | 0.35% | -1.21% | Sep 2026 |
| Lazard Baylight US Sm Cap Eq WW Dist EUR | 102K | 0.30% | +0.61% | Jul 2026 |
| Adara Smaller Companies | 84.8K | 0.25% | -0.39% | Sep 2026 |
| North Square Dynamic Small Cap I | 80.6K | 0.23% | -30.38% | Jun 2026 |
| iShares Micro-Cap ETF | 80.5K | 0.23% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 64.5K | 0.19% | 0.00% | Sep 2026 |
| CREF Total Global Stock Account R3 | 62.2K | 0.18% | -4.96% | Sep 2026 |
| 1290 Essex Small Cap Growth I | 51.1K | 0.15% | +0.53% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 49.5K | 0.14% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 45.8K | 0.13% | -0.05% | Sep 2026 |
Top institutions holding NPCE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Polar Capital Holdings PLC | 3.30M | 9.58% | 0.00% | Jun 2026 |
| Soleus Capital Management, L.P. | 2.91M | 8.45% | -0.72% | Jun 2026 |
| First Light Asset Management, LLC | 2.86M | 8.31% | +16.31% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.65M | 7.71% | +3.41% | Jun 2026 |
| BlackRock Inc | 2.48M | 7.20% | +5.59% | Jun 2026 |
| Orbimed Advisors LLC | 1.51M | 4.37% | -28.21% | Jun 2026 |
| Driehaus Capital Management LLC | 1.45M | 4.20% | -0.29% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.23M | 3.56% | +9.20% | Jun 2026 |
| Deutsche Bank AG | 939K | 2.73% | +0.73% | Jun 2026 |
| Armistice Capital, LLC | 692K | 2.01% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 666K | 1.94% | +7.79% | Jun 2026 |
| FMR Inc | 555K | 1.61% | +0.22% | Jun 2026 |
| State Street Corp | 550K | 1.60% | +10.57% | Jun 2026 |
| Silvercrest Asset Management Group LLC | 344K | 1.00% | -4.43% | Jun 2026 |
| Northern Trust Corp | 260K | 0.76% | +8.42% | Jun 2026 |
| Qube Research & Technologies | 221K | 0.64% | +18.82% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 220K | 0.64% | +17.58% | Jun 2026 |
| Palumbo Wealth Management LLC | 209K | 0.61% | -0.60% | Jun 2026 |
| Essex Investment Management Company, LLC | 209K | 0.61% | -4.15% | Jun 2026 |
| Algert Global LLC | 185K | 0.54% | +2.91% | Jun 2026 |
Neuropace Inc company profile
- Company name
- Neuropace Inc
- Ticker
- NPCE.US
- Exchange
- USA Stocks
- Listed since
- Apr 22, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 216
- Fiscal year end
- December
- Address
- 455 North Bernardo Avenue, Mountain View, CA, United States, 94043
- Phone
- 650 237 2700
- Website
- neuropace.com
About Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Neuropace Inc management
10- Mr. Joel D. BeckerCEO, President & Director · born 1968
- Mr. Patrick F. WilliamsChief Financial Officer · born 1973
- Dr. Martha J. Morrell M.D.Chief Medical Officer · born 1957
- Mr. Dylan St. JohnChief of Operations & Development
- Mr. Scott R. SchaperHead of Investor Relations
- Ms. Leah AkinGeneral Counsel & Corporate Secretary
- Ms. Katie KellerVice President of Marketing
- Mr. Chris ReeseSenior Vice President of Sales
- Ms. Amy TreadwellVice President of Human Resources
- Ms. Julie HsuVP & Controller